Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences, Inc. (SPRB) is a clinical-stage biopharmaceutical company pioneering non-steroidal therapies for rare endocrine disorders. This page serves as the definitive source for verified news and developments surrounding SPRB's innovative research and clinical programs.
Investors and medical professionals will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated content includes updates on SPRB's lead candidate tildacerfont for congenital adrenal hyperplasia (CAH), financial disclosures, and scientific conference presentations.
Key information categories include:
- Clinical trial phase updates
- Regulatory agency communications
- Peer-reviewed research publications
- Strategic industry collaborations
- Financial performance summaries
Bookmark this page for direct access to SPRB's official announcements, maintaining informed perspectives on therapeutic advancements in endocrine care.
Spruce Biosciences, Inc. (NASDAQ: SPRB), a biopharmaceutical company focused on rare endocrine disorders, will participate in two investor conferences in November 2022. The conferences include the Credit Suisse 31st Annual Healthcare Conference from November 7-10, where the company will present on November 8 at 2:35 p.m. PT, and the Jefferies 2022 London Healthcare Conference from November 15-17, featuring 1x1 meetings. Webcast access and replays will be available on the company’s investor relations website.
Spruce Biosciences (NASDAQ: SPRB) announced that Samir Gharib, President and CFO, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 5:00 pm ET. The company focuses on developing therapies for rare endocrine disorders, with its lead candidate, tildacerfont, targeting classical congenital adrenal hyperplasia (CAH). This condition has lacked new treatments for around 50 years. Interested parties can access the live webcast here.
Spruce Biosciences (Nasdaq: SPRB) reported its Q2 2022 financial results, highlighting a net loss of $11.9 million, consistent with the previous year. The company achieved over 25% enrollment in both CAHmelia-203 and CAHmelia-204 studies. P.J. Ramtin has been appointed as Senior VP of Business Operations, bringing extensive industry experience. The patent portfolio for tildacerfont expanded with two new patents, extending exclusivity through 2038. Cash and investments totaled $99.1 million at quarter-end, with R&D expenses rising to $9.1 million as the company progresses clinical development.
Spruce Biosciences (NASDAQ: SPRB) announces participation in two investor conferences in June 2022. The Jefferies Healthcare Conference will take place from June 8-10, 2022, featuring a company presentation on June 8 at 4:00 PM ET. The JMP Securities Life Sciences Conference follows on June 15-16, 2022, highlighted by a fireside chat on June 16 at 11:30 AM ET. Webcasts of both events will be accessible via Spruce's investor relations website, with replays available for 30 days. Spruce is focused on therapies for rare endocrine disorders, including potential treatments for congenital adrenal hyperplasia.
Spruce Biosciences (NASDAQ: SPRB) announced an abstract acceptance for a poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) in Atlanta, GA, scheduled for June 11-14, 2022. The presentation will cover survey results assessing patient perceptions on glucocorticoid treatment for congenital adrenal hyperplasia (CAH). Key details include the session date of June 11, 2022, from 1:00 p.m. to 3:00 p.m. ET, presented by Dr. Chris N. Barnes. The company aims to develop non-steroidal therapies for CAH and is also exploring treatments for polycystic ovary syndrome (PCOS).
Spruce Biosciences (Nasdaq: SPRB) reported progress in its CAHmelia-203 study for adult classic congenital adrenal hyperplasia (CAH), achieving 25% enrollment and expects topline data by H2 2023. The company amended its debt facility with Silicon Valley Bank for a $10 million credit line, reducing interest rates. R&D expenses rose to $8.5 million, while total operating expenses increased to $11.7 million, resulting in a net loss of $11.8 million for Q1 2022. The patent portfolio for tildacerfont has also expanded, enhancing market exclusivity.
Spruce Biosciences (NASDAQ: SPRB) announced its participation in two upcoming investor conferences in May 2022. The first event is the RBC Capital Markets Global Healthcare Conference on May 17-18, featuring a fireside chat on May 17 at 10:00 a.m. ET. The second event is the H.C. Wainwright Global Investment Conference from May 23-26, with a company presentation on May 25 at 4:00 p.m. ET. Interested investors can access webcasts via the company’s investor relations website. Spruce focuses on therapies for rare endocrine disorders.
Spruce Biosciences, Inc. (NASDAQ: SPRB) has appointed Libbie Mansell, Ph.D., M.B.A., R.A.C., as its Chief Regulatory and Quality Officer. Dr. Mansell will lead global regulatory affairs and quality strategy as the company advances its drug tildacerfont for rare endocrine disorders, including congenital adrenal hyperplasia and polycystic ovary syndrome. With over 30 years of experience in regulatory affairs, she aims to enhance Spruce's pipeline of treatments for significant unmet medical needs. CEO Javier Szwarcberg highlights her extensive expertise as a critical addition to the team.
Spruce Biosciences, Inc. (Nasdaq: SPRB) reports its fourth quarter and annual financial results for 2021, highlighting progress in developing treatments for rare endocrine disorders. The company anticipates topline safety data from its Phase 2 Pediatric Classic CAH study by 1H 2023. As of December 31, 2021, Spruce had cash and investments of $121.4 million, expected to fund operations into Q2 2024. R&D expenses increased to $30.7 million from $23.9 million in 2020. The net loss for 2021 was $42.3 million, compared to $29.5 million the previous year.
Spruce Biosciences, Inc. (NASDAQ: SPRB) has appointed Dr. Will Charlton as Chief Medical Officer following the departure of Dr. Rosh Dias. Dr. Charlton, with over 15 years in clinical research and experience in rare disease drug development, will lead Spruce's clinical strategies, particularly focusing on tildacerfont, aimed at treating classic congenital adrenal hyperplasia and polycystic ovary syndrome.
CEO Javier Szwarcberg expressed confidence in Dr. Charlton's expertise, anticipating significant advancements in therapies for rare endocrine disorders, which have seen no new treatments in nearly 50 years.
